Advertisement

Clinical Assisted Reproduction: The Effect of Exogenous Luteinizing Hormone (LH) on Oocyte Viability: Evidence from a Comparative Study Using Recombinant Human Follicle-Stimulating Hormone (FSH) Alone or in Combination with Recombinant LH for Ovarian Stimulation in Pituitary-Suppressed Women Undergoing Assisted Reproduction

  • Juan Balasch
  • Montserrat Creus
  • Francisco Fábregues
  • Salvadora Civico
  • Francisco Carmona
  • Bienvenido Puerto
  • Roser Casamitjana
  • Juan A. Vanrell
Article

Abstract

Purpose: The purpose of this prospective, randomized study was to compare ovarian response and oocyte and embryo yields in women undergoing ovulation induction for IVF/ICSI using recombinant human FSH (rhFSH) alone or in combination with recombinant human LH (rhLH).

Methods: Patients were randomized to receive rhFSH alone (group F; n = 13) or rhFSH + rhLH (group L; n = 15). rhFSH was administered according to a step-down protocol; patients assigned to group L received rhLH at a fixed dose of 75 IU (1 ampoule) throughout the treatment period.

Results: The total dose of rhFSH, number of growing follicles, and serum concentrations of estradiol (E2) on the day of hCG administration were similar in both treatment groups. However, the percentage of metaphase II oocytes and fertilization rate were significantly higher in group F than in group L. The lower fertilization rates associated with rhLH were also seen in a subgroup of patients from group L who had undergone a previous ART cycle stimulated with FSH only and thus acted as their own controls. However, when in vitro fertilization (IVF) and intracytoplasmic sperm injection cycles were considered separately, differences in fertilization rates were statistically significant only for oocytes treated by conventional IVF.

Conclusions: This study shows that the addition of recombinant LH to recombinant FSH in pituitary-suppressed women undergoing ART does not improve the ovarian response and even may have a negative impact on oocyte maturation and fertilization.

IVF LH oocyte viability recombinant LH 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Filicori M: Gonadotropin-releasing hormone analogs in ovulation induction: currents status and perspectives. J Clin Endocrinol Metab 1996;81:2413-2416Google Scholar
  2. 2.
    Lunenfeld B, Lunenfeld E: Gonadotropic preparations-Lessons learned. Fertil Steril 1997;67:812-814Google Scholar
  3. 3.
    Hull MGR, Armatage RJ, McDermott A: Use of follicle-stimulating hormone alone (urofollitropin*) to stimulate the ovaries for assisted conception after pituitary desensitization. Fertil Steril 1994;62:997-1003Google Scholar
  4. 4.
    Loumaye E, Engrand P, Howles CM, et al.: Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization outcome. Fertil Steril 1997;67:889-899Google Scholar
  5. 5.
    Daya S: hMGversus FSH: Is there any difference? In Ovulation Induction: Update' 98, M Filicori, C Flamigni (eds). New York, Parthenon Publishing Group, 1998, pp 183-192Google Scholar
  6. 6.
    Söderström-Anttila V: Clinical outcome of ovulation induction: highly purified FSH versus hMG. In Ovulation Induction: Update' 98, M Filicori, C Flamigni (eds). New York, Parthenon Publishing Group, 1998, pp 193-200Google Scholar
  7. 7.
    Filicori M: The role of luteinizing hormone in folliculogenis and ovulation induction. Fertil Steril 1999;71:405-414Google Scholar
  8. 8.
    Chappel SC, Howles C: Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206-1212Google Scholar
  9. 9.
    Fleming R, Chung CC, Yates RWS, et al.: Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod 1996;11:1854-1858Google Scholar
  10. 10.
    Pieters MHEC, Dumoulin JCM, Engelhart CM, et al.: Immaturity and aneuploidy in human oocytes after different stimulation protocols. Fertil Steril 1991;56:306-310Google Scholar
  11. 11.
    Balasch J, Fábregues F, Creus M, et al.: Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization. Hum Reprod 1996;11:2400-2404Google Scholar
  12. 12.
    The European Recombinant Human LH Study Group: Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH-and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998;83:1507-1514Google Scholar
  13. 13.
    Veeck LL: Atlas of the Human Oocyte and Early Conceptus. Baltimore, Williams & Wilkins, 1986Google Scholar
  14. 14.
    Jacobson A, Marshall JR: Ovulatory response rate with human menopausal gonadotropins of varying FSH-LH ratios. Fertil Steril 1969;20:171-175Google Scholar
  15. 15.
    Louwerens B: The clinical significance of the FSH/LH ratio in gonadotropin preparations of human origin. A review. Acta Obstet Gynecol Scand 1969;48 (Suppl 1):31-40Google Scholar
  16. 16.
    Balasch J, Miró F, Burzaco I, et al.: The role of luteinizing hormone in human follicle development and oocyte fertility: Evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod 1995; 10:1678-1683Google Scholar
  17. 17.
    Fox R, Ekeroma A, Wardle P: Ovarian response to purified FSH in infertile women with long-standing hypogonadotropic hypogonadism. Aust NZ J Obstet Gynaecol 1997;37:92-94Google Scholar
  18. 18.
    Cortvrindt R, Hu Y, Smitz J: Recombinant luteinizing hormone as a survival and differentiation factor increases oocyte maturation in recombinant follicle stimulating hormone-supplemented mouse preantral follicle culture. Hum Reprod 1998;13:1292-1302Google Scholar
  19. 19.
    Hillier SG: Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994;9:188-191Google Scholar
  20. 20.
    Zelinski-Wooten MB, Hutchinson JS, Hess DL, et al.: Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod 1995;10:1658-1666Google Scholar
  21. 21.
    Weston AM, Zelinski-Wooten MB, Hutchinson JS, et al.: Developmental potential of embryos produced by invitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone. Hum Reprod 1996;11:608-613Google Scholar
  22. 22.
    Kelly EE, Nebiolo L: Recombinant FSH therapy alone versus combination therapy with recombinant LH therapy in patients down-regulated with a low-dose luteal GnRH agonist protocol: Preliminary results. In Towards Reproductive Certainty: Fertility & Genetics Beyond 1999, R Jansen, D Mortimer (eds). New York, Parthenon Publishing Group, 1999, pp. 200-204Google Scholar
  23. 23.
    Sills ES, Levy DP, Moomjy M, et al.: A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum Reprod 1999;14:2230-2235Google Scholar
  24. 24.
    Bukovsky A, Chen TT, Wimalasena J, et al.: Cellular localization of luteinizing hormone receptor immunoreactivity in the ovaries of immature, gonadotropin-primed and normal cycling rates. Biol Reprod 1993;48:1367-1382Google Scholar
  25. 25.
    Schreiber JR, Reed R, Ross GT: A receptor-like testosterone-binding protein in ovaries from estrogen-stimulated hypophysectomized immature female rats. Endocrinology 1976;98:1206-1213Google Scholar
  26. 26.
    Erickson GF, Magoffin DA, Dyer CA, et al.: The ovarian androgen producing cells: A review of structure/function relationships. Endocrin Rev 1985;6:371-399Google Scholar
  27. 27.
    Rodgers M, McLoughlin J, Peers N, et al.: Accumulation of human chorionic gonadotrophin in the serum of patients during in-vitro fertilization treatment cycles with Pergonal. Hum Reprod 1994;9:638-642Google Scholar
  28. 28.
    Eshkol A: Recombinant gonadotrophins: An introduction. Hum Reprod 1996;11 (Suppl 1):89-94Google Scholar
  29. 29.
    Siebold B: Physicochemical characterization of recombinant human follicle stimulating hormone. Hum Reprod 1996;11 (Suppl 1):109-115Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Juan Balasch
    • 1
  • Montserrat Creus
    • 1
  • Francisco Fábregues
    • 1
  • Salvadora Civico
    • 1
  • Francisco Carmona
    • 1
  • Bienvenido Puerto
    • 1
  • Roser Casamitjana
    • 2
  • Juan A. Vanrell
    • 1
  1. 1.Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine—University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain
  2. 2.Hormonal Laboratory, Faculty of Medicine—University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain

Personalised recommendations